Plaque Psoriasis

An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

A comparative assessment shows children with psoriasis have a four-fold increased risk of reaching PASI 75 with biologics.

How primary care fits into the scheme of patient management, and what new therapies may mean for atopic dermatitis.